Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03723993
Other study ID # R123
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 15, 2018
Est. completion date December 15, 2018

Study information

Verified date February 2021
Source Fayoum University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of study is to detect effect of remote ischemic preconditioning on serum lactate levels during and after cardiac surgery with cardiopulmonary bypass in addition to its effect on cardiac and renal clinical outcomes.


Description:

Remote ischemic preconditioning (RIPC) is a phenomenon where transient non-injurious ischemia/ reperfusion episodes applied to an organ away from the heart can protect the myocardium from ischemia/reperfusion injury. RIPC has been found to be an attractive strategy to reduce myocardial injury and improve outcome in patients undergoing cardiac surgery. The exact mechanisms of this protection are not yet known, although stimulation of prosurvival intracellular kinase responses and inhibition of inflammatory pathways each play a role. RIPC can be performed by noninvasive inflation and deflation of a standard blood pressure cuff or pneumatic tourniquet on the upper or lower limbs to induce brief ischemia and reperfusion, which is the mechanism by which injury in patients undergoing open cardiac surgery occurs. ANESTHETIC TECHNIQUE All patients will be preoperatively examined and investigated by complete blood count, coagulation profile, renal and kidney functions and electrolytes. Electrocardiography, chest x ray and echocardiography will be routinely done. Coronary angiography and carotid arterial duplex will be requested in patients prepared for coronary artery bypass graft (CABG). Patient will be premedicated by intramuscular injection of 10mg morphine in the morning of the operation. Before induction of anesthesia, a five-lead electrocardiography system will be applied to monitor heart rate, rhythm, and ST segments (leads II and V5). A pulse oximeter probe will be attached, and a peripheral venous cannula will be placed. For measurement of arterial pressure and blood sampling, a 20 G cannula will be inserted into either right or left radial artery under local anesthesia. General anesthesia will be induced by fentanyl (3-5 μg/kg), propofol titrated according to response, followed by atracurium (0.5 mg/kg). Trachea will be intubated, patients will be mechanically ventilated with oxygen in air so as to achieve normocarbia. This will be confirmed by radial arterial blood gas analysis. An esophageal temperature probe and a Foley catheter will also be placed. For drug infusion, a triple-lumen central venous catheter will be inserted via the right internal jugular vein. Anesthesia will be maintained by inhaled isoflurane, with additional fentanyl injected prior to skin incision as well as sternotomy and atracurium infusion for continued muscle relaxation. During extracorporeal circulation, patients will receive propofol infusion in addition to atracurium infusion. Before initiation of cardiopulmonary bypass (CPB), the patients will receive intravenously tranexamic acid (2 g) and heparin (300-500 units/kg body weight) to achieve an activated clotting time > 400 s. CPB was instituted via an ascending aortic cannula and a two-stage right atrial cannula. Before, during, and after CPB (pump blood flow: 2.4 l/min/m2), mean arterial pressure was adjusted to exceed 60 mmHg. Cardiac arrest will be induced with cold antegrade crystalloid cardioplegia (St Thomas solution) or warm intermittent antegrade blood cardioplegia. Lactate-enriched Ringer's solution will be added to the CPB circuit to maintain reservoir volume when needed, and packed red blood cells will be added when hemoglobin concentration decrease to less than 7 g/dl. After rewarming the patient to 37°C and separation from CPB, reversal of heparin by protamine sulfate, and sternal closure, the patients will be transferred to the intensive care unit.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 15, 2018
Est. primary completion date November 15, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years of age or older - Elective cardiovascular surgery requiring cardiopulmonary bypass either for CABG or valve replacement. Exclusion Criteria: - Patients with emergency surgeries. - Off pump heart surgery. - Hepatic affection (INR>2). - Renal affection (creatinine >1.6 mg/dl for men and >1.4 mg/dl for women). - Peripheral vascular disease affecting upper limbs. - Patients taking the antidiabetic sulphonylurea glyburide ( glibenclamide) or receiving nicorandil drug therapy will be excluded because these agents have been shown to abolish preconditioning. - Patients being considered for radial artery conduit harvesting.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Inflated cuff
After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
Non inflated cuff
non inflated cuff around the arm for the control group

Locations

Country Name City State
Egypt Mohamed Hamed Fayoum

Sponsors (1)

Lead Sponsor Collaborator
Fayoum University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Badreldin AM, Doerr F, Elsobky S, Brehm BR, Abul-dahab M, Lehmann T, Bayer O, Wahlers T, Hekmat K. Mortality prediction after cardiac surgery: blood lactate is indispensible. Thorac Cardiovasc Surg. 2013 Dec;61(8):708-17. doi: 10.1055/s-0032-1324796. Epub 2013 Mar 11. Erratum in: Thorac Cardiovasc Surg. 2013 Jun;61(4):375. Elsobky, Sherif [removed]. Thorac Cardiovasc Surg. 2014 Apr; 62(3):273. Elsobky, Sherif [added]. — View Citation

Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013 Jan 12;381(9861):166-75. doi: 10.1016/S0140-6736(12)60916-7. Epub 2012 Oct 22. Review. — View Citation

Saxena P, Newman MA, Shehatha JS, Redington AN, Konstantinov IE. Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg. 2010 Jan-Feb;25(1):127-34. doi: 10.1111/j.1540-8191.2009.00820.x. Epub 2009 Jun 22. Review. — View Citation

Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013 Aug 17;382(9892):597-604. doi: 10.1016/S0140-6736(13)61450-6. Erratum in: Lancet. 2013 Sep 14;382(9896):940. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Age in years 1 hour before operation once the patient is recruited
Primary Serum lactate level mmol/l from arterial blood gas sample 1 minute at the end of operation
Secondary Serum lactate level mmol/l from arterial blood gas sample 3 minutes after induction of anesthesia
Secondary Serum lactate level mmol/l from arterial blood gas sample 30 minutes, after cardiopulmonary bypass
Secondary Serum lactate level mmol/l from arterial blood gas sample 1 minute before cardiopulmonary bypass
Secondary Serum lactate level mmol/l from arterial blood gas sample 24 hours postoperatively.
Secondary Serum lactate level mmol/l from arterial blood gas sample 48 hours postoperatively.
Secondary Serum lactate level mmol/l from arterial blood gas sample 72 hours postoperatively.
Secondary Heart rate beat per minute from electrocardiogram 2 minutes before induction of general anesthesia
Secondary Heart rate beat per minute from electrocardiogram 3 minutes after induction of general anesthesia
Secondary Heart rate beat per minute from electrocardiogram Every 30 minutes for 6 hours during surgery except at cardiopulmonary bypass as there is cardioplegia
Secondary Systolic blood pressure Measured by mmHg from invasive arterial blood pressure 2 minutes before induction of general anesthesia
Secondary Systolic blood pressure Measured by mmHg from invasive arterial blood pressure 3 minutes after induction
Secondary Systolic blood pressure Measured by mmHg from invasive arterial blood pressure Every 30 minutes for 6 hours during surgery except at cardiopulmonary bypass as there is cardioplegia and no pulsatile blood pressure
Secondary Diastolic blood pressure Measured by mmHg from invasive arterial blood pressure 2 minutes before induction of general anesthesia
Secondary Diastolic blood pressure Measured by mmHg from invasive arterial blood pressure 3 minutes after induction
Secondary Diastolic blood pressure Measured by mmHg from invasive arterial blood pressure Every 30 minutes for 6 hours during surgery except at cardiopulmonary bypass as there is cardioplegia and no pulsatile blood pressure
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 12 hours before the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 2 hours after the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 4 hours after the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 12 hours after the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 24 hours after the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 48 hours after the operation
Secondary Left ventricular fractional shortening (LVFS) measured in percentage derived from echocardiography 72 hours after the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 12 hours before the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 2 hours after the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 4 hours after the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 12 hours after the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 24 hours after the operation
Secondary Left ventricular ejection fraction (LVEF) measured in percentage derived from echocardiography 48 hours after the operation
Secondary Central venous pressure from central venous catheter measured in cm H2O Baseline 2 minutes after insertion of central venous catheter
Secondary Central venous pressure from central venous catheter measured in cm H2O 2 minutes before cardiopulmonary bypass
Secondary Central venous pressure from central venous catheter measured in cm H2O 2 minutes after cardiopulmonary bypass
Secondary Central venous pressure from central venous catheter measured in cm H2O 1 minute after the end of operation
Secondary Serum urea level mmol/L 5 minutes before beginning of operation
Secondary Serum urea level mmol/L 5 minutes after ICU admission
Secondary Serum creatinine level mmol/L 5 minutes before beginning of operation
Secondary Serum creatinine level mmol/L 24 hours postoperatively
Secondary Serum creatinine level mmol/L 48 hours postoperatively
Secondary Serum creatinine level mmol/L 72 hours postoperatively
Secondary Acute kidney injury (AKI) score Grade 1: serum creatinine rise of 150%-200% of baseline and/or urine output <0.5 mL/kg/h for >6 contiguous hours.
Grade 2: serum creatinine rise of 200%-300% of baseline and/or urine output <0.5 mL/kg/h for >12 contiguous hours.
Grade 3: serum creatinine rise of >300% of baseline and/or urine output <0.3 mL/kg/h for >24 h or anuria for 12 h.
24 hours postoperatively
Secondary Acute kidney injury (AKI) score Grade 1: serum creatinine rise of 150%-200% of baseline and/or urine output <0.5 mL/kg/h for >6 contiguous hours.
Grade 2: serum creatinine rise of 200%-300% of baseline and/or urine output <0.5 mL/kg/h for >12 contiguous hours.
Grade 3: serum creatinine rise of >300% of baseline and/or urine output <0.3 mL/kg/h for >24 h or anuria for 12 h.
48 hours postoperatively
Secondary Acute kidney injury (AKI) score Grade 1: serum creatinine rise of 150%-200% of baseline and/or urine output <0.5 mL/kg/h for >6 contiguous hours.
Grade 2: serum creatinine rise of 200%-300% of baseline and/or urine output <0.5 mL/kg/h for >12 contiguous hours.
Grade 3: serum creatinine rise of >300% of baseline and/or urine output <0.3 mL/kg/h for >24 h or anuria for 12 h.
72 hours postoperatively
Secondary Serum sodium level milliequivalent/L 5 minutes after ICU admission.
Secondary Serum sodium level milliequivalent/L 5 minutes before beginning of operation
Secondary Serum potassium level milliequivalent/L 5 minutes before beginning of operation
Secondary Serum potassium level milliequivalent/L 5 minutes after ICU admission
Secondary Arterial oxygen pressure From arterial blood gas sampling 5 minutes before operation
Secondary Arterial oxygen pressure From arterial blood gas sampling 2 minutes before cardiopulmonary bypass
Secondary Arterial oxygen pressure From arterial blood gas sampling 2 minutes after cardiopulmonary bypass
Secondary Arterial oxygen pressure From arterial blood gas sampling 1 minute after end of operation
Secondary Arterial oxygen pressure From arterial blood gas sampling Every 6 hours for 24 hours in the ICU
Secondary Arterial carbon dioxide pressure From arterial blood gas sampling 5 minutes before operation
Secondary Arterial carbon dioxide pressure From arterial blood gas sampling 2 minutes before cardiopulmonary bypass
Secondary Arterial carbon dioxide pressure From arterial blood gas sampling 2 minutes after cardiopulmonary bypass
Secondary Arterial carbon dioxide pressure From arterial blood gas sampling 1 minute after end of operation
Secondary Arterial carbon dioxide pressure From arterial blood gas sampling Every 6 hours for 24 hours in the ICU
Secondary Power of hydrogen (pH) From arterial blood gas sampling 5 minutes before operation
Secondary Power of hydrogen (pH) From arterial blood gas sampling 2 minutes before cardiopulmonary bypass
Secondary Power of hydrogen (pH) From arterial blood gas sampling 2 minutes after cardiopulmonary bypass
Secondary Power of hydrogen (pH) From arterial blood gas sampling 1 minute after end of operation
Secondary Power of hydrogen (pH) From arterial blood gas sampling Every 6 hours for 24 hours in the ICU
Secondary Standard bicarbonate level From arterial blood gas sampling 5 minutes before operation
Secondary Standard bicarbonate level From arterial blood gas sampling 2 minutes before cardiopulmonary bypass
Secondary Standard bicarbonate level From arterial blood gas sampling 2 minutes after cardiopulmonary bypass
Secondary Standard bicarbonate level From arterial blood gas sampling 1 minute after end of operation
Secondary Standard bicarbonate level From arterial blood gas sampling Every 6 hours for 24 hours in the ICU
See also
  Status Clinical Trial Phase
Withdrawn NCT00638040 - The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression N/A
Completed NCT00004493 - Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia Phase 2
Completed NCT00004490 - Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis Phase 3
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Recruiting NCT03126890 - Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions
Completed NCT01873859 - Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media N/A
Terminated NCT01354652 - Lactic Acidosis During Entecavir(ETV)Treatment Phase 4
Terminated NCT02974257 - Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest Phase 2
Active, not recruiting NCT05984186 - Wingate-type Exercise Test to Evaluate the Effect of High Velocity Therapy on Recovery Sensation and Blood Lactate Decline
Completed NCT01139463 - Study of Blood Lactate Levels in Patients Treated With Antipsychotics N/A
Completed NCT01901419 - Nitroglycerin Infusion During Cardiac Surgery N/A
Completed NCT00202228 - Lactate Metabolism Study in HIV Infected Persons Phase 4
Completed NCT04975906 - The Threshold of Serum Anion Gap as a Screening Tool for Organic Acidosis
Completed NCT00942123 - Study On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis N/A
Withdrawn NCT01973504 - Phase 2c Dose Comparison Study of MP4OX in Trauma Phase 2
Completed NCT00015015 - Dichloroacetate Kinetics, Metabolism and Toxicology N/A
Completed NCT00004353 - Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia N/A
Completed NCT03466528 - Alcohol: Thiamine and or Magnesium 1 Phase 2/Phase 3